Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Summit-07: A randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain.

Markman J, Gudin J, Rauck R, Argoff C, Rowbotham M, Agaiby E, Gimbel J, Katz N, Doberstein SK, Tagliaferri M, Lu L, Siddhanti S, Hale M.

Pain. 2019 Feb 8. doi: 10.1097/j.pain.0000000000001517. [Epub ahead of print]

PMID:
30747908
2.

NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential.

Miyazaki T, Choi IY, Rubas W, Anand NK, Ali C, Evans J, Gursahani H, Hennessy M, Kim G, McWeeney D, Pfeiffer J, Quach P, Gauvin D, Riley TA, Riggs JA, Gogas K, Zalevsky J, Doberstein SK.

J Pharmacol Exp Ther. 2017 Oct;363(1):104-113. doi: 10.1124/jpet.117.243030. Epub 2017 Aug 4.

PMID:
28778859
3.

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.

Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, Rubas W, Doberstein SK, Eldon M, Hoch U, Zalevsky J.

PLoS One. 2017 Jul 5;12(7):e0179431. doi: 10.1371/journal.pone.0179431. eCollection 2017.

4.

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.

Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, Sheng D, Liu X, Sims PW, VanderVeen LA, Ali CF, Chang TK, Konakova M, Pena RL, Kanhere RS, Kirksey YM, Ji C, Wang Y, Huang J, Sweeney TD, Kantak SS, Doberstein SK.

Clin Cancer Res. 2016 Feb 1;22(3):680-90. doi: 10.1158/1078-0432.CCR-15-1631.

5.

Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.

Harding TC, Long L, Palencia S, Zhang H, Sadra A, Hestir K, Patil N, Levin A, Hsu AW, Charych D, Brennan T, Zanghi J, Halenbeck R, Marshall SA, Qin M, Doberstein SK, Hollenbaugh D, Kavanaugh WM, Williams LT, Baker KP.

Sci Transl Med. 2013 Mar 27;5(178):178ra39. doi: 10.1126/scitranslmed.3005414.

6.

Discovery of a cytokine and its receptor by functional screening of the extracellular proteome.

Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT.

Science. 2008 May 9;320(5877):807-11. doi: 10.1126/science.1154370.

7.

Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection.

Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE.

J Immunol. 2007 Aug 1;179(3):1872-83.

8.

HTS technologies in biopharmaceutical discovery.

Wu G, Doberstein SK.

Drug Discov Today. 2006 Aug;11(15-16):718-24. Review.

PMID:
16846799
9.

Inactivation of TNF signaling by rationally designed dominant-negative TNF variants.

Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, Abbott C, Carmichael D, Chan C, Cherry L, Cheung P, Chirino AJ, Chung HH, Doberstein SK, Eivazi A, Filikov AV, Gao SX, Hubert RS, Hwang M, Hyun L, Kashi S, Kim A, Kim E, Kung J, Martinez SP, Muchhal US, Nguyen DH, O'Brien C, O'Keefe D, Singer K, Vafa O, Vielmetter J, Yoder SC, Dahiyat BI.

Science. 2003 Sep 26;301(5641):1895-8.

10.

Dynamic localization of myosin-I to endocytic structures in Acanthamoeba.

Ostap EM, Maupin P, Doberstein SK, Baines IC, Korn ED, Pollard TD.

Cell Motil Cytoskeleton. 2003 Jan;54(1):29-40.

PMID:
12451593
11.

rolling pebbles (rols) is required in Drosophila muscle precursors for recruitment of myoblasts for fusion.

Rau A, Buttgereit D, Holz A, Fetter R, Doberstein SK, Paululat A, Staudt N, Skeath J, Michelson AM, Renkawitz-Pohl R.

Development. 2001 Dec;128(24):5061-73.

12.

Regulation of DAF-2 receptor signaling by human insulin and ins-1, a member of the unusually large and diverse C. elegans insulin gene family.

Pierce SB, Costa M, Wisotzkey R, Devadhar S, Homburger SA, Buchman AR, Ferguson KC, Heller J, Platt DM, Pasquinelli AA, Liu LX, Doberstein SK, Ruvkun G.

Genes Dev. 2001 Mar 15;15(6):672-86.

13.

Termination of phototransduction requires binding of the NINAC myosin III and the PDZ protein INAD.

Wes PD, Xu XZ, Li HS, Chien F, Doberstein SK, Montell C.

Nat Neurosci. 1999 May;2(5):447-53.

PMID:
10321249
14.

Genetic analysis of myoblast fusion: blown fuse is required for progression beyond the prefusion complex.

Doberstein SK, Fetter RD, Mehta AY, Goodman CS.

J Cell Biol. 1997 Mar 24;136(6):1249-61.

15.

Fluorescent erythrocyte ghosts as standards for quantitative flow cytometry.

Doberstein SK, Wiegand G, Machesky LM, Pollard TD.

Cytometry. 1995 May 1;20(1):14-8.

16.

Dependence of calmodulin localization in the retina on the NINAC unconventional myosin.

Porter JA, Yu M, Doberstein SK, Pollard TD, Montell C.

Science. 1993 Nov 12;262(5136):1038-42.

PMID:
8235618
17.

Inhibition of contractile vacuole function in vivo by antibodies against myosin-I.

Doberstein SK, Baines IC, Wiegand G, Korn ED, Pollard TD.

Nature. 1993 Oct 28;365(6449):841-3.

PMID:
8413668
18.

Primary structure of and studies on Acanthamoeba actophorin.

Quirk S, Maciver SK, Ampe C, Doberstein SK, Kaiser DA, VanDamme J, Vandekerckhove JS, Pollard TD.

Biochemistry. 1993 Aug 24;32(33):8525-33.

PMID:
8357799
19.

Moving off the beaten track.

Atkinson SJ, Doberstein SK, Pollard TD.

Curr Biol. 1992 Jun;2(6):326-8. No abstract available.

PMID:
15335948
20.
21.
22.

Mechanism of the interaction of human platelet profilin with actin.

Goldschmidt-Clermont PJ, Machesky LM, Doberstein SK, Pollard TD.

J Cell Biol. 1991 Jun;113(5):1081-9.

23.

Myosin-I.

Pollard TD, Doberstein SK, Zot HG.

Annu Rev Physiol. 1991;53:653-81. Review. No abstract available.

PMID:
2042976

Supplemental Content

Loading ...
Support Center